HomeCompareAE vs JNJ

AE vs JNJ: Dividend Comparison 2026

AE yields 2.53% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $2.7K in total portfolio value· pulled ahead in Year 9
10 years
AE
AE
● Live price
2.53%
Share price
$37.98
Annual div
$0.96
5Y div CAGR
12.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.6K
Annual income
$1,142.72
Full AE calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AE vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAEJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AE + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AE pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AE
Annual income on $10K today (after 15% tax)
$214.85/yr
After 10yr DRIP, annual income (after tax)
$971.31/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,014.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AE + JNJ for your $10,000?

AE: 50%JNJ: 50%
100% JNJ50/50100% AE
Portfolio after 10yr
$28.9K
Annual income
$2,916.06/yr
Blended yield
10.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AE
No analyst data
Altman Z
8.8
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AE buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAEJNJ
Forward yield2.53%2.13%
Annual dividend / share$0.96$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR12.9%28%
Portfolio after 10y$27.6K$30.3K
Annual income after 10y$1,142.72$4,689.40
Total dividends collected$6.2K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AE vs JNJ ($10,000, DRIP)

YearAE PortfolioAE Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,985$285.37$10,592$272.30+$393.00AE
2$12,085$330.78$11,289$357.73+$796.00AE
3$13,315$383.96$12,123$472.89+$1.2KAE
4$14,693$446.36$13,141$629.86+$1.6KAE
5$16,242$519.73$14,408$846.81+$1.8KAE
6$17,985$606.17$16,021$1,151.60+$2.0KAE
7$19,952$708.23$18,122$1,588.22+$1.8KAE
8$22,178$829.02$20,930$2,228.20+$1.2KAE
9← crossover$24,702$972.31$24,792$3,191.91$90.00JNJ
10$27,574$1,142.72$30,274$4,689.40$2.7KJNJ

AE vs JNJ: Complete Analysis 2026

AEStock

Adams Resources & Energy, Inc., through its subsidiaries, primarily engages in the marketing, transportation, terminalling, and storage in various crude oil and natural gas basins in the United States. The company operates through three segments: Crude Oil Marketing, Transportation and Storage; Tank truck Transportation of Liquid Chemicals, Pressurized Gases, Asphalt and Dry Bulk; and Pipeline Transportation, Terminalling and Storage of Crude Oil. It purchases crude oil and arranges sales and deliveries to refiners and other customers primarily onshore in Texas, Oklahoma, North Dakota, Michigan, Wyoming, and Louisiana; and owns and operates a fleet of 201 tractor-trailer rigs and maintains approximately 180 pipeline inventory locations or injection stations. The company also transports liquid chemicals, pressurized gases, asphalt, and dry bulk on a for hire basis in the continental United States, and into Canada and Mexico; and operates nineteen truck terminals in Houston, Corpus Christi, Nederland, Freeport, Baton Rouge, St. Rose, Boutte, Sterlington, Jacksonville, Tampa, Atlanta, Augusta, Alabama, North Carolina, Ohio, West Virginia, Arkansas, East St. Louis, Joliet, Louisiana, and the Corpus Christi. In addition, it operates crude oil and condensate pipeline system, which connects the Eagle Ford Basin to the Gulf Coast waterborne market that has a capacity of 450,000 barrels per day. Adams Resources & Energy, Inc. was founded in 1947 and is headquartered in Houston, Texas.

Full AE Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AE vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AE vs SCHDAE vs JEPIAE vs OAE vs KOAE vs MAINAE vs ABBVAE vs MRKAE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.